Types of Covid-19 Vaccines and Titbits
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against COVID-19. Prior to the COVID-19 pandemic, work to develop a vaccine against the coronavirus diseases SARS and MERS had established knowledge about the structure and function of coronaviruses, which accelerated development during early 2020 of varied technology platforms for a COVID‑19 vaccine.
Countries are currently offering the coronavirus (COVID-19) vaccine to people most at risk from coronavirus.
Pfizer COVID-19 vaccine safe and effective
Pfizer and BioNTech's COVID-19 vaccine is safe, effective and produces robust antibody responses in 12- to 15-year olds, the companies said, paving the way for them to seek U.S. and European approval to use the shot in this age group within weeks.
​
​
Moderna Vaccine
The Moderna COVID‑19 vaccine, codenamed mRNA-1273, is a COVID‑19 vaccine developed by the United States National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and Moderna. It is administered by two 0.5 mL doses given by intramuscular injection given four weeks apart
AstraZeneca/Oxford vaccine
The AstraZeneca/Oxford vaccine has the major advantages of being inexpensive, costing about £2.50 ($3.40, N1400.29k) per dose, and easy to store. It can be kept at normal refrigerator temperatures of between two and eight degrees Celsius (36-46 Fahrenheit). It can be kept at normal refrigerator temperatures of between two and eight degrees Celsius (36-46 Fahrenheit).
​The Oxford-AstraZeneca COVID-19 vaccine uses a chimpanzee adenoviral vector. It delivers the gene that encodes the SARS-CoV-2 spike protein to our cells.
Johnson & Johnson Vaccine
The Johnson & Johnson COVID-19 vaccine is a human adenovirus viral vector COVID-19 vaccine developed by Janssen Vaccines in Leiden in The Netherlands, and its Belgian parent company Janssen Pharmaceuticals, subsidiary of American company Johnson & Johnson (J&J).
The vaccine is based on a human adenovirus that has been modified to contain the gene for making the spike protein of the SARS-CoV-2virus that causes COVID-19.
Who is Eligible for Covid-19 Vaccine?
UN says 26 countries in Africa have received 15 million vaccines
The United Nations has stated that 15 million vaccines have been shared among 26 African nations under the COVAX scheme, as of March 21, 2021.
This was disclosed by Antonio Guterres, UN Secretary-General, during a virtual meeting with the African Group at the UN on Tuesday.
“As I have said again and again, a COVID-19 vaccine must be a global public good available to everyone, everywhere. Vaccine equity is a moral test of global solidarity.
“We see many examples of vaccine nationalism and vaccine hoarding in wealthier countries, as well as continued side deals with manufacturers that undermine access for all.
“The world needs to unite to produce and distribute sufficient vaccines for all, which means at least doubling manufacturing capacity around the world,” Guterres said.
​
Guterres also used the meeting to reiterate his appeal for debt relief for African countries to “ease the economic and social fallout of the crisis’’.
The organisation says more than $2 billion (N776 billion) is still needed under COVAX to fully meet its goal to vaccinate those most in need by the end of the year.
We Take Pride in Covid-19 Vaccine Figures
W.H.O Approved Vaccines
As of September, 2021
2
Approved Number of Doses
158M
Vaccines
36.5M
Vaccinated (1st Jab)
51
Countries in Africa
8
Our Partners
